Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

Vaccine

Volumn 23, Issue 20, 2005, Pages 2591-2601

  Vandepapelière, Pierre ^a   Rehermann, Barbara ^b   Koutsoukos, Marguerite ^a   Moris, Philippe ^a   Garçon, Nathalie ^a   Wettendorff, Martine ^a   Leroux Roels, Geert ^c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adjuvants; AS02A; CTL; Cytotoxicity; HBV; Vaccination

Indexed keywords

AS02A ADJUVANT; CD8 ANTIGEN; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HLA A2 ANTIGEN; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; QS 21; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIAPHORESIS; EMULSION; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HELPER CELL; HEPATITIS B; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; INJECTION SITE REACTION; MEDICAL ASSESSMENT; MYALGIA; PAIN; PRIORITY JOURNAL; RECIPIENT; RIGOR; SWEATING; T LYMPHOCYTE; VACCINATION;

EID: 15044365661     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.11.034     Document Type: Article

References (43)

1. R.A. Koup, J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, and W. Borkowsky Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type I syndrome J Virol 68 7 1994 4650 4655
2. D. Wodarz Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses J Gen Virol 84 7 2003 1743 1750
3. L.L. Perry, K. Feilzer, and H.D. Caldwell Immunity to Chlamydia trachomatis is mediated by T-helper 1 cells through IFN-gamma-dependant and -independant pathways J Immunol 158 7 1997 3344 3352
4. E.H. Nardin, and R.S. Nussenzweig T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages Annu Rev Immunol 11 1993 687 727
5. S. Stenger, and R.L. Modlin T cell mediated immunity to Mycobacterium tuberculosis Curr Opin Microbiol 2 1999 89 93
6. N.L. Letvin, B.R. Bloom, and S.L. Hoffman Prospects for vaccines to protect against AIDS, tuberculosis and malaria JAMA 285 5 2001 606 611
7. M.W. Cho, Y.B. Kim, M.K. Lee, K.C. Gupta, W. Ross, and R. Plishka Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques J Virol 75 2001 2224 2234
8. P. Sun, R. Schwenk, K. White, J.A. Stoute, J. Cohen, and W.R. Ballou Protective immunity induced with malaria vaccine, RTS-S, is linked to Plasmodium falciparum circumsporozoite protein specific CD4+ and CD8+ T cells producing IFN-γ J Immunol 171 2003 6961 6967
9. G.J. Gorse, M.J. Campbell, E.E. Otto, D.C. Powers, G.W. Chambers, and F.K. Newman Increased anti-influenza A virus cytotoxic T cell activity following vaccination of chronically ill elderly with live attenuated or inactivated influenza virus vaccine J Infect Dis 172(s) 1995 1 10
10. R. Nanan, A. Rauch, E. Kämpgen, S. Niewiesk, and H.W. Kreth A novel sensitive approach for frequency analysis of measles virus-specific memory T-lymphocytes in healthy adults with a childhood history of natural measles J Gen Virol 81 2000 1313 1319
11. S.M. Blower, K. Koelle, D.E. Kirschner, and J. Mills Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety Proc Natl Acad Sci USA 98 6 2001 3618 3623
12. The AIDS Vaccine Evaluation Group (AVEG 022) Protocol Team Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type I Env, Gag and Pro in combination with RGP120 J Infect Dis 183 2001 563 570
13. D.C. Tang, M. De Vit, and S.A. Johnson Genetic immunization is a simple method for eliciting an immune response Nature 356 1992 152 154
14. S. Gurunathan, C.Y. Wu, B.L. Freidag, and R.A. Seder DNA vaccines: a key for inducing long-term cellular immunity Curr Opin Immunol 12 2000 442 447
15. D.H. Barouch, and N.L. Letvin DNA vaccination for HIV-1 and SIV Intervirology 43 2000 282 287
16. D.H. Barouch, J. Kunstman, M.J. Kuroda, J.E. Schmitz, S. Santra, and F.W. Peyerl Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 415 2002 335 339
17. D.T. O'Hagan, M.L. MacKichan, and M. Singh Recent developments in adjuvants for vaccines against infectious diseases Biomol Eng 18 2001 69 85
18. Kenney RT, Rabinovich NR, Pichyangkul S, Price VL, Enlers HD. In: Proceedings of the Second Meeting on Novel Adjuvants currently in/close to Human Clinical Testing, World Health Organization-Fondation Mérieux, Annecy, France, 5-7 June 2000. Vaccine 2002; 20:2155-63.
19. R. Edelman The development and use of vaccine adjuvants Mol Biotechnol 21 2002 129 148
20. J.C. Cox, and A.R. Coulter Adjuvants: a classification and review of their modes of action Vaccine 15 3 1997 248 256
21. N. Garçon, D.G. Heppner, and J. Cohen Development of RTS,S/AS02A: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant Expert Rev Vaccines 2 2 2003 231 238
22. A. Lalvani, P. Moris, G. Voss, A.A. Pathan, K.E. Kester, and R. Brookes Potent induction of focused Thl-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine J Infect Dis 180 1999 1656 1664
23. S. Mc Cormack, A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, and A. Newberry A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gpl20 (W61D) derived from dual tropic R5X4 HIV-1ACH320 Vaccine 18 2000 1166 1177
24. Ribi E, Cantrell J, Feldner T, Myers K, Peterson J. Biological activities of monophosphoryl lipid A. In: Levin L, et al., editors. Microbiology. Washington, DC: American Society of Microbiology; 1986.
25. C.R. Kensil, and R. Kammer QS-21: a water-soluble triterpene glycoside adjuvant Exp Opin Invest Drugs 7 9 1998 1475 1482
26. P. Vandepapeliere, M. Slaoui, E. Lebacq, G. Leroux-Roels, and M. Delchambre Vaccine therapy for chronic hepatitis B: immunogenicity and safety of two candidate vaccines in human healthy volunteers. Proceedings of the 36th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) New Orleans 1996 1418
27. G. Leroux-Roels, I. Desombere, G. De Tollenaere, M.A. Petit, P. Desmons, and P. Hauser Hepatitis B vaccine containing surface antigen and selected pre-Sl and pre-S2 sequences. 1. Safety and immunogenicity in young healthy adults Vaccine 15 16 1997 1724 1731
28. J. Van Hattum, M.C. Rash, and G.J. Boland Early evaluation of two schedules of administration of a novel therapeutic vaccine for chronic hepatitis B Hepatology 32 2000 458A
29. U. Bienzle, M. Günther, R. Neuhaus, P. Vandepapeli-re, J. Vollmar, and A. Lyn Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B related disease Hepatology 38 2003 811 819
30. J. Petre, T. Rutgers, and P. Hauser Properties of a recombinant yeast-derived hepatitis B surface antigen containing S, preS2 and preSl antigenic domains Arch Virol Suppl. 4 1992 137 141
31. B. Rehermann, P. Fowler, J. Sidney, J. Person, A. Redeker, and M. Brown The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis J Exp Med 181 1995 1047 1058
32. A.G. Johnson, M. Tomai, L. Solem, L. Beck, and E. Ribi Characterization of a non-toxic monophosphoryl lipid A Rev Infect Dis 9 Suppl. 5 1987 S512 S516
33. G. De Becker, V. Moulin, B. Pajak, C. Bruck, M. Francotte, and C. Thiriart The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells Intern Immunol 12 6 2000 807 815
34. L.R. Stanberry, S.L. Spruance, A.L. Cunningham, D.I. Bernstein, A. Mindel, and S. Sacks Glycoprotein-D-adjuvant vaccine to prevent genital herpes N Engl J Med 347 2002 1652 1661
35. C.R. Kensil, U. Patel, M. Lennick, and D. Marciani Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex J Immunol 146 2 1991 431 437
36. J.A. Stoute, M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, and P. Desmons A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group N Engl J Med 336 1997 86 91
37. K.A. Bojang, P.J. Milligan, M. Pinder, L. Vigneron, A. Alloueche, and K.E. Kester Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomized trial Lancet 358 2001 1927 1934
38. G. Voss, K. Manson, D. Montefiori, D.I. Watkins, J. Heeney, and M. Wyand Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine J Virol 77 2 2003 1049 1058
39. C.M. Gerard, N. Baudson, K. Kraemer, C. Bruck, N. Garçon, and Y. Paterson Therapeutic potential of protein and adjuvant vaccinations on tumour growth Vaccine 19 2001 2583 2589
40. R. Bertoni, A. Sette, J. Sidney, L.G. Guidotti, M. Shapiro, and R. Purcell Human class I supertypes and CTL repertoires extend to chimpanzees J Immunol 161 1998 4447 4455
41. R. Bertoni, J. Sidney, P. Fowler, R.W. Chesnut, F.V. Chisari, and A. Sette Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis J Clin Invest 100 3 1997 503 513
42. R. Schirmbeck, K. Melber, A. Kuhrober, Z.A. Janowics, and J. Reimann Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo J Immunol 152 1994 1110 1119
43. R.K. Gupta, E.H. Relyveld, E.B. Lindblad, B. Bizzini, S. Ben-Efraim, and C.K. Gupta Adjuvants: a balance between toxicity and adjuvanticity Vaccine 11 3 1993 293 306